NFKB1 and coronary artery disorder: Studies on the pharmacological mechanism of the Tongmai Yangxin Pill (TMYXP), a patented CM, revealed that TMYXP attenuates foam cell formation and lipid deposits by regulating ESR1 and NF-κB signaling pathways, improving CHD patients' biochemical indices (Fan et al., 2021) (Table 1).